NCT00216203 - Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Pemetrexed

Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles

DRUG

Cetuximab

"Cetuximab 400 mg/m2, week 1, day 1~Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle"

Trial Locations (11)

Greenebaum Cancer Center, Baltimore

Oncology Hematology Care, Inc., Cincinnati

Indiana University Cancer Center, Indianapolis

Elkhart Clinic, Elkhart

Center for Cancer Care at Goshen Health System, Goshen

Northern Indiana Cancer Research Consortium, South Bend

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

Medical Consultants, P.C., Muncie

Cancer Care Center of Southern Indiana, Bloomington

Medical & Surgical Specialists, LLC, Galesburg

Texas Oncology Cancer Center, Austin